Checkpoint Cell Therapy
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
90
NCT04426669
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 15, 2020
Completion: Jan 31, 2026
NCT05566223
CISH Inactivated TILs in the Treatment of NSCLC
Start: Feb 28, 2023
Completion: Nov 30, 2027
Loading map...